
    
      This is a multi-centre, open-label, non-randomized, single treatment, safety and efficacy
      study. All subjects who completed the LA29-0207 study are eligible for participation.
      Participants will receive deferiprone oral solution at the same dose (20 or 40 mg/kg/day)
      that they were assigned for LA29-0207. The duration of treatment will be 52 weeks.
    
  